A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT.

Published on Oct 1, 2019in Clinical Nuclear Medicine6.587
· DOI :10.1097/RLU.0000000000002703
Birgit Pernthaler1
Estimated H-index: 1
(Medical University of Graz),
Roman Kulnik3
Estimated H-index: 3
+ 3 AuthorsHerbert Kvaternik6
Estimated H-index: 6
PurposeOne of the major challenges for all imaging modalities is accurate detection of prostate cancer (PCa) recurrence. Beyond the established 68Ga-PSMA, a novel promising PET tracer in PCa imaging is 18F-fluciclovine. For evaluating the advantages and disadvantages and the comparability, we conduc
📖 Papers frequently viewed together
108 Citations
1 Citations
43 Citations
Cited By26
#1Ian Alberts (University of Bern)H-Index: 10
#2Robert Seifert (DKFZ: German Cancer Research Center)
Last. Ali Afshar-Oromieh (University of Bern)H-Index: 37
view all 4 authors...
Prostate-specific membrane antigen-PET/computed tomography (PSMA-PET/CT) is the investigation of choice for imaging prostate cancer. Demonstrating high diagnostic accuracy, PSMA-PET/CT detects disease at very early stages of recurrence, where the chances of a definitive cure may be at their greatest. A number of PSMA-radioligands are in established clinical routine, and there are currently only limited data and no single tracer can clearly be advocated over the others at present. Further clinica...
#1Ashesh B. Jani (Emory University)H-Index: 35
#2Eduard Schreibmann (Emory University)H-Index: 28
Last. David M. Schuster (Emory University)H-Index: 33
view all 19 authors...
Summary Background Molecular imaging is increasingly used to guide treatment decisions and planning in prostate cancer. We aimed to evaluate the role of 18F-fluciclovine-PET/CT in improving cancer control compared with conventional imaging (bone scan and either CT or MRI) alone for salvage postprostatectomy radiotherapy. Methods In EMPIRE-1, a single-centre, open-label, phase 2/3 randomised controlled trial, patients with prostate cancer with detectable PSA after prostatectomy and negative conve...
#1Soroush Rais-Bahrami (UAB: University of Alabama at Birmingham)H-Index: 48
#2Jason A. Efstathiou (Harvard University)H-Index: 55
Last. Andrew Scarsbrook (University of Leeds)H-Index: 29
view all 8 authors...
BACKGROUND A systematic literature review of the performance of 18Fluorine-fluciclovine PET/CT for imaging of men with recurrent prostate cancer was performed. METHODS Scientific literature databases (MEDLINE, ScienceDirect and Cochrane Libraries) were searched systematically during Oct 2020 using PRISMA criteria. No limit was put on the date of publication. Prospective studies reporting a patient-level 18F-fluciclovine detection rate (DR) from ≥25 patients with recurrent prostate cancer were so...
1 CitationsSource
#1Grant Harmon (LUC: Loyola University Chicago)H-Index: 4
#2Dennis Chan Md (LUC: Loyola University Chicago)
Last. Abhishek A. Solanki (LUC: Loyola University Chicago)H-Index: 11
view all 11 authors...
Abstract Purpose We used the patterns of recurrence on 18F-fluciclovine PET/CT in post-prostatectomy patients enrolled in the XXXX trial to evaluate how well the most recent NRG Oncology and Groupe Francophone de Radiotherapie Urologique (GFRU) contouring recommendations encompassed all sites of recurrence in the prostate fossa and pelvic nodes in comparison to former Radiation Therapy Oncology Group (RTOG) recommendations. Methods Patients with biochemically recurrent prostate cancer after radi...
#1Therese Seierstad (Oslo University Hospital)H-Index: 20
#2Knut Håkon Hole (Oslo University Hospital)H-Index: 17
Last. Eivor Hernes (Oslo University Hospital)H-Index: 13
view all 7 authors...
The PET tracer 18F-fluciclovine (Axumin) was recently approved in the United States and Europe for men with suspected prostate cancer recurrence following prior treatment. This article summarizes studies where systematic sector-based histopathology was used as reference standard to assess the diagnostic accuracy of the tracer 18F-fluciclovine PET in patients with prostate cancer.
1 CitationsSource
ABSTRACT Prostate cancer (PC) is one of the most common cancers affecting men worldwide, with a high recurrence rate after therapy. 68Ga-PSMA-11 and 18F-fluciclovine are PET imaging tracers for the detection of recurrence sites in PC patients. 68Ga-PSMA-11 is a membrane antigen overexpressed by tumor cells, whereas 18F-fluciclovine targets increased amino acid transporter in the membrane of cancer cells. We report a case of an 83-year-old man with known oligodendroglioma and biochemically recurr...
#1Courtney Lawhn-Heath (UCSF: University of California, San Francisco)H-Index: 7
#2Ali Salavati (Johns Hopkins University)
Last. Thomas A. HopeH-Index: 39
view all 10 authors...
Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals are playing a large role at the time of initial staging and biochemical recurrence for localizing prostate cancer, as well as in other emerging clinical settings. PSMA PET has demonstrated increased detection rate compared with conventional imaging and has been shown to change management plans in a substantial percentage of cases. The aims of this narrative review are to highlight the development and clinical impact of PSMA ...
#1Luca F. Valle (UCLA: University of California, Los Angeles)H-Index: 3
#1Luca F. Valle (UCLA: University of California, Los Angeles)H-Index: 8
Last. Amar U. Kishan (UCLA: University of California, Los Angeles)H-Index: 19
view all 9 authors...
Abstract Context The use, common findings, and impact of modern molecular positron emission tomography (PET)/computed tomography (CT) imaging prior to salvage radiation therapy (RT) in men with biochemical recurrence after radical prostatectomy (RP) have not been evaluated comprehensively. Objective We performed a scoping systematic review of the literature assessing detection rates, detection patterns, changes in management, as well as changes in patient outcome resulting from molecular PET/CT ...
1 CitationsSource
#2Cinzia RomagnoloH-Index: 1
Last. Luca BurroniH-Index: 1
view all 8 authors...
Background: to explore the diagnostic accuracy of 18F-Fluciclovine positron-emission tomography (PET) in prostate cancer (PCa), considering both primary staging prior to radical therapy, biochemical recurrence, and advanced setting. Methods: A systematic web search through Embase and Medline was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Studies performed from 2011 to 2020 were evaluated. The terms used were “PET” or “positr...
#1Ao LiuH-Index: 4
#2Miao Zhang (SJTU: Shanghai Jiao Tong University)H-Index: 7
Last. Danfeng XuH-Index: 10
view all 9 authors...
Purpose This study aimed to evaluate the clinical utility of 18F-PSMA-1007 positron emission tomography (PSMA PET)/magnetic resonance imaging (MRI) imaging in patients with suspected or defined prostate cancer. Methods In the pilot study, we retrospectively investigated 62 patients who underwent PSMA-PET/MRI for suspected or defined PCa between June 2019 and June 2020. Patients were grouped into three subgroups: (1) suspected PCa without histological evidence, (2) primary PCa, (3) biochemical re...